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Abstract
Objective: The objective was to deepen the understanding of the causes of individual variability in phenylketonuria
(PKU) by investigating which metabolic variables are most important for predicting cognitive outcomes (Phe
average vs Phe variation) and by assessing the risk of cognitive impairment associated with adopting a more
relaxed approach to the diet than is currently recommended.
Method: We analysed associations between metabolic and cognitive measures in a mixed sample of English and
Italian early-treated adults with PKU (N = 56). Metabolic measures were collected through childhood, adolescence
and adulthood; cognitive measures were collected in adulthood. Metabolic measures included average Phe levels
(average of median values for each year in a given period) and average Phe variations (average yearly standard
deviations). Cognition was measured with IQ and a battery of cognitive tasks.
Results: Phe variation was as important, if not more important, than Phe average in predicting adult outcomes and
contributed independently. Phe variation was particularly detrimental in childhood. Together, childhood Phe
variation and adult Phe average predicted around 40% of the variation in cognitive scores. Poor cognitive scores (>
1 SD from controls) occurred almost exclusively in individuals with poor metabolic control and the risk of poor
scores was about 30% higher in individuals with Phe values exceeding recommended thresholds.
Conclusions: Our results provide support for current European guidelines (average Phe value = < 360 μmol/l in
childhood; = < 600 μmo/l from 12 years onwards), but they suggest an additional recommendation to maintain
stable levels (possibly Phe SD = < 180 μmol/l throughout life).
Public significance statements: We investigated the relationship between how well people with phenylketonuria
control blood Phe throughout their life and their ability to carry out cognitive tasks in adulthood. We found that
avoiding blood Phe peaks was as important if not more important that maintaining average low Phe levels. This
was particularly essential in childhood. We also found that blood Phe levels above recommended European
guidelines was associated with around 30% increase in the risk of poor cognitive outcomes.
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Background
Phenylketonuria (PKU; OMIM#261600) is an inherited
metabolic disease where a genetic error results in a par-
tial or complete de-activation of the enzyme phenylalan-
ine hydroxylase (PAH) which normally metabolizes the
amino acid phenylalanine (Phe; E.C. 1.14.16.1) into tyro-
sine (a precursor of dopamine). Phe accumulation results
in several and still incompletely known negative effects
on the postnatal development of the brain as well as on
the functioning of the mature brain [1]. Fortunately,
these negative consequences can be controlled by adopt-
ing, since birth, a Phe-restricted diet and protein supple-
mentation. There is no question that a low Phe diet
must be followed throughout childhood to achieve good
cognitive outcomes [2]. However, several questions re-
main open [3]. We need to know more about: 1. which
measures are most important to consider for dietary
control (Phe average vs Phe fluctuations); 2. the impact
of dietary control on different cognitive functions and
possible interactions with age; and 3. which Phe value
should be considered safe at different developmental
age; there is uncertainty especially regarding the levels
which are safe after early childhood. The purpose of this
study is to provide some evidence relevant to these ques-
tions by analysing the performance of a mixed group of
English and Italian early treated adults with PKU (from
now on AwPKU) in relation to the current and historical
blood phenylalanine control.
Which metabolic measure? (average Phe levels vs Phe
variation)
Blood Phe levels are usually measured with the assump-
tion that they correlate with levels in the brain (see
Leuzzi et al. [4]; Pietz et al. [5]; Rupp et al. [6], but also
Brumm et al. [7], Moats et al. [8]; Schindeler et al. [9]
for no relationship. Different measures of blood Phe
have been found to correlate with cognitive perform-
ance, but their relative contribution is unclear (from
now on Phe without qualification refers to blood Phe).
Most studies have assessed the impact of dietary con-
trol by considering either current Phe levels or average
levels across a time period (also referred to as IDC-
index of dietary control). Average levels have generally
been calculated as a mean of yearly median values or,
more rarely as a mean of half-year median values (for
examples of this latter measure see Pietz et al. [10];
Vilaseca et al. [11]). These studies have shown that
current Phe levels as well as average Phe levels are good
predictors of cognition (for examples of positive associa-
tions in adults across cognitive functions see Brumm
et al. [7]; Romani et al. [12]; for effects on IQ see Manti
et al. [13]; Weglage et al. [14]; for effects on IQ in chil-
dren, see Waisbren et al. [2]). Note, however, that effects
are limited when only a restricted set of tasks is used
[15, 16] and/or when only current Phe level has been
considered; for example, effects of current Phe on IQ
have been inconsistent across studies (see Jahja et al.
[17]; Moyle et al. [18] for positive and/or marginal re-
sults; see Koch et al. [19]; Feldmann et al. [20]; Pietz
et al. [10], for no correlation).
Phe variation (also referred to as Phe fluctuation by
some authors) has also been shown to predict cognition.
Phe variation has generally been measured as a mean of
yearly SD of Phe values [21–23]. Most studies have con-
sidered children and found that indexes of variation pre-
dict IQ (Burgard et al. [24]; Hood et al. [25]; marginally
significant results in Anastasoaie et al. [21]; see also
Vilaseca et al. [11] for results with a mixed-age group),
executive functions [22, 24], motor control [26], white
matter integrity [27]; for a review across functions, see
Cleary et al. [28]. There is more limited evidence that
Phe variation predicts cognitive outcomes long-term,
since studies on adult patients are lacking.
Viau et al. [23] studied a mixed sample of children and
young adults (N = 55) and assessed the impact of current
and historical Phe on cognition. They reported limited
correlations with Phe averages and no correlations at all
with Phe SD. However, cognition was measured only
with limited subtests from the WAIS and the WISC
(Block design, Symbol Search and Verbal IQ or Verbal
comprehension). Our previous study on a sample of 37
English AwPKU, early treated and with good metabolic
control, showed significant effects of both historical Phe
average and Phe SD (0–10, 11–16, 17+) on adult cogni-
tive performance measured through IQ and an ad-hoc
PKU battery of cognitive tasks [12].1 Importantly, how-
ever, these results did not provide information on the
relative contribution of Phe average and Phe SD to cog-
nitive outcomes. These two measures are, in principle,
independent of one another. Two individuals can main-
tain the same average Phe level, but one may show little
variation around the mean, with values very similar to
one another, while another may show a lot of variation.
Thus, both average Phe and Phe variation may contrib-
ute independently to good cognitive outcomes. However,
in practice, these two measures are highly correlated in
PKU populations, because individuals who maintain a
lower Phe average, also maintain a more consistent low
Phe diet [11, 12, 23, 25].
Hood et al. [25] reported some independent contribu-
tions of Phe SD, but they only assessed relationships in
children and with limited cognitive measures (they
found an independent contribution of childhood SD 5–
1Life-time Phe SD predicted FIQ and visuo-motor coordination; child-
hood Phe SD predicted visuo-spatial attention, complex EF and mem-
ory and learning; adolescence Phe SD predicted spoken language and
adult Phe SD predicted sustained attention.
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10 at years or after 10 years on matrix reasoning and
number of non-responses in an N-back task). In our
study, we aim to assess an independent contribution of
Phe SD on adult cognitive outcomes assessed more
comprehensively.
Individual variation in cognitive outcomes
While it is clear that cognitive outcomes depend on
metabolic control, the extent of this dependence is
debatable.
One question relates to whether all effects of having
PKU can be eliminated through dietary control [1]. We
know that most early-treated AwPKU perform within
the norm, but that, as a group, their performance is
worse than the controls. What we do not know, how-
ever, is whether the whole distribution of cognitive
scores is shifted so that even performance at the high-
end of the distribution is affected, or, instead, it is only
the lower end of the distribution which is affected,
where individuals are likely to have maintained poor
dietary control. The first option will indicate that there
are some fixed costs of having PKU which are not avoid-
able even maintaining a low Phe diet following current
treatment guidelines. The second option instead, will in-
dicate that a strict diet can completely eliminate the cog-
nitive impact of having PKU.
A second, related question concerns the safe target
range for blood Phe control at different ages. Current
European guidelines advise to maintain Phe average
levels below 360 μmol/L, before 12 years of age and
below 600 μmol/L thereafter [29, 30]. American guide-
lines are even more strict recommending 120–360 μmol/
L throughout life (American College of Medical Genetics
and Genomics, ACMG) [31]. However, even the Euro-
pean guidelines have been criticized for being over strin-
gent [32]. This is because there is little evidence of ill-
effects when guidelines are relaxed in adulthood [13]
and even the evidence to advocate childhood Phe < 360
is not strong [33–36]. A way to examine this question is
to examine the distributions of cognitive scores within
the PKU group in relation to metabolic control (see
Waisbren et al. [2] for analyses of children data). This
will allow us to examine if there are discontinuities in
the distributions of cognitive scores, with pathological
scores starting to appear and/or become more frequent
when a given metabolic value is exceeded and whether
these boundaries are consistent with current guidelines.
Additionally, the cost of not following guidelines can be
quantified by comparing the rates of poor cognitive
scores in individuals which have or have not followed
guidelines.
A final, related question, is whether there are individ-
uals who have maintained poor metabolic control, but
still have escaped cognitive impact. This will show that
there is variability on how negatively PKU affects cogni-
tion (see van Vliet et al. [37] for a review of extreme
case).
In conclusion, our study has two related aims: 1. To
compare the effects of protracted exposure of brain to
Phe –best measured through average Phe levels— with
the effects of Phe peaks –best measures through SD
from the mean--, and possible interactions with age. We
want to see whether both average Phe and Phe SD
contribute to adult outcomes and whether these two
measures have a different weight in childhood and ado-
lescence/adulthood. 2. To assess cognitive variability in a
population of adults with PKU to see a) whether effects
are pervasive or limited to a portion of individuals, b)
whether the Phe boundaries identified by current Euro-
pean guideline are meaningful and c) whether there are
exceptional cases where good cognition is achieved in
spite of poor metabolic control.
To achieve aims, we have combined results from
English and Italian AwPKU tested with the same battery
of tasks (N = 56). Italian and English sub-samples show
similar patterns of cognitive impairments and relation-
ships with current and historical Phe measures, justifying
accruing results (Romani et al., unpublished data). The
resulting sample is larger and more varied in terms of
metabolic control than most sets reported in the litera-
ture allowing better assessment of correlations between
metabolic and cognitive variables (current Phe range is
54–2081; SD = 403; compared, for example, to: Brumm
et al. [7]: 157–1713; SD = 338; Channon et al. [38]: 221–
1233; SD = 261; Jahjia et al. [17]: 66–1550; SD = 342;
Smith et al. [39]: 200–1879).
Method
Recruitment
Fifty six early-treated adult PKU participants were
tested: 19 Italian and 37 English. They were all diag-
nosed soon after birth as result of national newborn
screening programs.
The 19 Italian AwPKU were recruited from the
Clinical Centre for Neurometabolic Diseases Depart-
ment of Human Neuroscience, Child Neurology and
Psychiatry Unit, Sapienza University of Rome. Three
participants were currently treated with Kuvan. Nineteen
Italian control participants were recruited among friends
and students of the researchers. They were matched to
the Italian PKU participants for age and education.
Among the Italian participants, 4 had a diagnostic Phe
level > 600 μmol/L but < 1200 μmol/L; 15 participants
had Phe > 1200 μmol/L at birth.
The 37 English AwPKU participants were recruited
from the Department of Inherited Metabolic Disorders
at the University Hospitals Birmingham. They all had
Phe > 1200 μmol/L at birth. The performance of this
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sample on a larger set of tasks as been described in pre-
vious publications [12, 40, 41]. Thirty English healthy
controls were recruited through an advertising volun-
teering website. They were matched to the English PKU
participants for age and education.
All AwPKU treated in the English and Italian centres
were invited to participate and were accepted in the
study on a first come, first served basis. The English
study received NHS ethical approval. The Italian study
was approved by the local ethics committee. All partici-
pants provided informed consent to the study.
Metabolic measures
For both the English and the Italian PKU participants
blood spots for blood Phe were taken regularly since
diagnosis in early infancy and extensive records were
available although there were limited data for a few
participants (6 UK participants lacked or had very
limited childhood data). We averaged Phe control in
three age bands: childhood: 0–10 years old, adoles-
cence: 11–16 years old, and adulthood: 17 years to
present. We have also averaged measures throughout
the life-time and considered current Phe level (for the
Italian group, Phe has been measured immediately be-
fore the testing session/s or close to it; for the UK
group, Phe has been measured immediately before the
two testing sessions and averaged). We considered
two types of measures: Phe average and Phe variation.
Phe average in each band was calculated by taking
the median values for each year and, then averaging
the yearly values. The median is the value set halfway
in a distribution of scores; it is generally used in the
PKU literature rather than the mean because the me-
dian is not influenced by Phe variations. It is particu-
larly, important to use the median in our study since
we want to contrast a measure of central tendency
(median, mean) with a measure of variation. Phe vari-
ation in each band was calculated by taking the SD
for each year and then averaging yearly values in the
band.
Cognitive assessment
Cognitive assessments were carried out in a quiet room
at the clinical centres in Birmingham and Rome by one
the psychologist on the team. The testing session for the
Italian participants lasted between 2 and 3 h. The
English participants were tested in two separate sessions
of similar length (a less extensive set of tasks was
administered to the Italian participants because of re-
source limitations). A few PKU participants were not
able to attend the second testing session which resulted
in some data points missing for some tests (N = 31 in-
stead of 37).
IQ was measured using, the Wechsler Adult
Intelligence Scale-Revised (WAIS-R, [42]) with the Italian
participants and the Wechsler abbreviated scale of
intelligence (WASI, [43]) with the English participants,
which includes the following subtests: Vocabulary, Block
Design, Similarities, and Matrix Reasoning. In addition,
participants were given a set of tasks chosen from the
larger set of tasks administered in our previous studies
[12, 40]. We chose tests which either showed a strong
difference between participants with PKU and controls
and/or strong correlations with metabolic measures. We
also gave precedence to tasks with non-linguistic stimuli
which did not need adapting across languages. There-
fore, we did not include tests of picture naming, reading,
spelling and orthographic knowledge (spoonerisms,
phoneme deletions). Accuracy in these tasks was very
good and not related to metabolic measures [12]. Speed
of processing was assessed with visual search tasks. To
reduce the number of tasks tapping similar functions, we
also did not administer the Tower of Hanoi, the lexical
learning task, the Stroop, and nonword repetition. Mea-
sures of STM (digit span and Corsi span) and a baseline
measure of peripheral speed of processing were included
for completeness and because of mixed results from the
literature (for impairments in digit span and nonword
repetition see Palermo et al. [40]; for contrasting results
see Brumm et al. [7], and Moyle et al. [18]; see also Jahja
et al. [17], for deficits with increasing working memory
load).
The following cognitive areas were assessed:
1. Visual Attention. This was assessed with four tasks
[12, 40]: 1.Simple Detection: Press a response button
as soon as a ladybird appears on the screen; 2.
Detection with Distractors: Press a button when a
ladybird appears on the screen alone or with a
green bug; in the second part of the task the
instruction was changed to press a button when a
green bug appears on the screen alone or with a
ladybird; 3. Feature Search: Detect a target among
distractors not sharing features by pressing a yes’
or no’ button (e.g., a red ladybird among green
bugs); 4. Conjunction Search: Detect a target among
distractors sharing features (e.g., red ladybird
among red bugs and green bugs). Both reaction
times (RT from now on) and accuracy measures
(error rates) were taken.
2. Visuo-motor Coordination. This was assessed
with two tasks: 1. Grooved Pegboard Test [44]: Put
pegs into the holes of a board using only one hand
as quickly as possible (short version with two trials
one with the dominant and one with the non-
dominant hand to match Italian and English sam-
ples) and 2. Digit Symbol Task [42]: Fill as many
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boxes as possible with symbols corresponding to
numbers (key with associations remains visible) in
90 s. Trail Making Test A (TMT A) [45, 46]:
connect circles containing numbers in ascending
order of the numbers as quickly as possible.
3. Complex Executive Functions. This was assessed
with four tasks tapping skills such as planning,
flexibility and abstract thinking: 1. The Wisconsin
Card Sorting Test (WCST) 64 card version [47]:
Discover the rules to match cards from a deck with
four reference cards according to the shape,
number or colour of the symbols on the card;
feedback is provided to allow learning. Flexibility is
required when the sorting rule is changed unknown
to the participant and the new rule must be
discovered. We used three different scores: total
errors, number of perseverative responses and
number of completed categories. 2. Difference in
speed between Trail Making Test B-A (TMT B-A)
[45, 46]. A involves connecting circles containing
numbers in ascending order; B also involves
connecting circles in ascending order, but
alternating between circles containing numbers and
letters . Only completion time is considered in this
test; when, occasionally, an error is made, it is cor-
rected by the examiner and this affects time to
complete the task. 3 Fluency: For letter fluency:
generate as many words as possible starting with a
given letter in one minute of time (for Italian: P, F
and L; Novelli et al. [48]; for English: C, F and L;
Benton et al. [49]); for semantic fluency [50, 51]:
generate as many names of animals as possible in
one minute of time. This requires planning an effi-
cient search through the lexicon.
4. Short-term Memory/Working Memory. This was
assessed with two tasks: 1. Digit Span: Repeat a
sequence of digits spoken by the examiner, soon
after presentation; 2. Corsi Block Tapping Test [52]:
The examiner taps a sequence of blocks and the
participant must reproduce the sequence in the
same order.
5. Sustained Attention – This was assessed with the
Rapid Visual Information Processing task (RVP;
adapted from Sahakian et al. [53]): detect three
target sequences of 3 digits by pressing the response
key when the last number of the sequence appears
on the screen. Scores are percentage correct.
6. Verbal Memory and Learning. This was assessed
with The Rey Auditory Verbal Learning Test [54,
55] which asks for learning, immediate recall, and
delayed recall of a list of 15 words. The list is
presented five times and participants are asked to
recall the words immediately after each
presentation. After the 5th presentation (A5), an
interfering list (B1) is presented and participants are
asked to recall this list and then, once again, the
original list (A6) without a further presentation.
Finally, participants are asked to recall the original
list after a 20-min filled interval. Our scores include
total number of errors across the five learning trials
(A1–5); errors in recalling the words after an
interfering list (A6); and, again, errors in delayed
recall of the original list.
7. Visual Memory and Learning. This was assessed
with the Paired Associates Visual Learning [56]:
Learn to associate objects with locations.
Demographics and preliminary analyses
Data analysis
For each participant, we computed z scores for each task
using the relative (Italian or English) control group as
reference. We also averaged z scores across tasks as a
measure of overall cognitive performance. We report re-
sults of the PKU group using z-scores. Group differences
of PKU from controls is examined through t-tests. Rela-
tionships between cognitive scores and Phe is examined
with Pearson bivariate correlations. To reduce the num-
ber of variables per task, we did not carry out correla-
tions with accuracy measures in search task (which are
not impaired), and we only correlated for the TMT, the
B-A condition; for the WCST, the total errors; and for
the Rey, performance over 1–5 trials (learning) and in
delay recall.
Participants
Table 1 shows demographic variables for age, gender,
years of education and Phe control across age. Average
Phe level increased across ages (diet became more re-
laxed), Phe variation remained more stable (see also
Hood et a [25]., for similar results in children up to 18
years old).
Cognitive outcomes
Cognitive performance across tasks is shown in Table 2.
Patterns of results are very similar to those reported pre-
viously with an overlapping sample of 37 AwPKU [40],
except for the visual paired-associate learning which
shows a modest group impairment. The tasks with the
largest differences from controls were tasks of visual
search measured in terms of speed of processing and
task involving visuo-motor coordination (pegboard, digit
symbol, TMT A). Executive functions in terms of flexi-
bility and planning, (TMT B, verbal fluency2) and sus-
tained attention were also impaired consistent with
previous results (see for speed of processing: Albrecht
2Note these tasks have also a speed component, although not as strong
as tasks measuring RTs.
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et al. [57]; visuo-motor coordination: Griffiths et al. [58];
Pietz et al. [10]; executive functions: Smith et al. [39];
Brumm et al. [7]; sustained attention: Schmidt at al [55].;
Bik-Multanowski et al. [59]; Weglage et al. [14]; Jahja
et al. [17]).
Cognitive outcomes in relation to metabolic control
Table 3 shows bivariate Pearson r correlations between
cognitive and metabolic measures. Correlations were ex-
tensive both for Phe average and Phe variations. Correla-
tions were significant both with current and historical
measures and for all tasks (except the Corsi span), al-
though they were not systematic across all ages and
types of metabolic measures. Significant correlations
with lifetime measures (either average or SD) were found
with IQ, speed in visual search, tasks tapping
visuo-motor coordination, EF (WCST, TMT-B-A and
Table 1 Demographic and metabolic information for English
and Italian PKU groups matched for age, gender and education,
and for the whole group. Blood Phe measured in μmol/L
PKU Group Control Group
N = 56 N = 49
Mean SD Mean SD
Age 26.8 6.4 26.5 6.3
Education (in years) 14.3 1.9 14.7 1.8
Gender (M/F) 21//35 21//28
VIQ 101.1 12.9 110.8 11.4
PIQ 102.7 15.2 110.1 11.1
FIQ 102.2 14.4 112.3 11.3
Childhood (0–10 years)
Phe Average Median 457 213
Phe Fluctuation 214 64
Mean N obs. Per participant 201 141
Adolescence (11–16 years)
Phe Average Median 714 294
Phe Fluctuation 162 56
Mean N obs. Per participant 78 65
Adulthood (17 years +)
Phe Average Median 859 307
Phe Variation 164 77
Mean N obs. Per participant 63 67
Lifetime
Phe Average Median 655 263
Phe Fluctuation (SD) 179 58
Mean N obs. Per participant 341 213
Current Phe 833 403
Range 65–2081
Table 2 Cognitive performance of the PKU group (English and
Italian PKU participants; N = 56). Z scores calculated from
respective control groups (N = 30 and N = 19). To facilitate
interpretation, for all scores, higher Z-score reflect worse
performance. Scores in bold are significantly higher than
expected. ms. = milliseconds; sec. = seconds
PKU Overall Z score
Mean SD Diff from controls
(t-test)
IQ 0.8 1.3 p < .001
Visual attention RTs
Simple Detection - ms. 0.3 1 n.s.
Detention with Distractors – ms. 0.8 1.6 p < .01
Feature Search – ms. 1.5 2.3 p < .001
Conjunction Search m. 1.2 1.7 p < .001
Visual attention accuracy
Detention with Distractors - % errors 0.2 1 n.s.
Feature Search - % errors 0.2 2.6 n.s
Conjunction Search - % errors −0.1 0.8 n.s
Visuo-motor coordination
Pegboard (sec.) 0.9 1.9 p < .01
Digit Symbol (%errors in 90 s.) 0.7 1.2 p < .01
Trail-Making Test A: (sec.) 0.8 1.9 p < .01
Executive functions
WCST
Total errors 0.4 1.6 n.s.
Perseverative responses 0.1 1.1 n.s.
N of Completed Categories 0.5 1.9 p = .06
Trail-Making Tests
B (sec.) 0.6 1.5 p = .01
B-A (sec.) 0.5 1.7 p = .06
Verbal Fluency
Letter (correct answers) 0.6 1 p < .01
Semantic (correct answers) 0.8 1.3 p < .001
Short term memory
Digit span 0.3 1.1 n.s.
Corsi Block span 0.0 1.1 n.s.
Sustained attention
RVP (% of errors) 0.7 1.3 p < .01
Learning
Rey Auditory Verbal Learning Test
Trial A1-A5 (% errors) 0.2 1.2 n.s.
Retention (% errors A6) 0.3 1.4 n.s.
Delayed Recall (% errors) 0.3 1.3 n.s.
Paired Associate Visual learning
(% errors) 0.7 1.9 p = .02
Overall (excluding IQ)
Mean 0.5 0.8 p < .001
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semantic fluency), sustained attention, Rey words de-
layed recall, and paired visual learning.
Consistent with previous results [12], tasks tapping
visuo-attentional speed were associated with blood Phe
early in life, but less with adult blood Phe and not at all
with current Phe level. AwPKU who had maintained a
more constant control in early childhood (0–10 years)
still showed positive effects many years later, in adult-
hood, with faster RTs. In contrast, other tasks correlated
strongly even with current Phe level. FSIQ, visuo-motor
coordination (digit symbol), sustained attention, TMT
B-A and learning are all strongly affected by current Phe
level (as well as by levels at previous years).
Phe average vs Phe SD
Data analyses
Effects of Phe average and Phe SD were compared with
different analyses. We compared the effect of these mea-
sures at different ages by contrasting correlations be-
tween Phe average/Phe SD in either childhood or
adulthood and adult cognitive outcomes. We compared
the number of significant correlations through χ2 tests
and average size of correlation with t-tests.
Furthermore, we compared the relative contribution of
Phe average and Phe SD to cognition by carrying out re-
gression analyses where cognition was measured with ei-
ther IQ or mean z-score in our cognitive battery as a
summary measure of performance (contribution of indi-
vidual measures is shown in the previous section with
correlation analyses). We carried out three types of re-
gressions. First of all, we compared the effects of Phe
average and Phe variation across the lifespan. We carried
out a two-steps regression where education was entered
in the first step (to partial out any contribution) and
both Phe average and Phe variation were entered to-
gether in the second step (forward method where the
variables making the strongest contribution is consid-
ered first and, then, any other variable which makes an
additional significant contribution is added). Note that
entering education at a first step is a conservative choice,
not only because there is a mutual relationship between
IQ and education (with education influencing IQ, but
also IQ influencing education), but also because Phe
levels may influence education. In a second analysis, we
assessed directly the contribution of Phe SD after Phe
average was considered. Therefore, Phe average was
forced in the first step and Phe variation was entered in
the second step. Finally, we carried out a third type of
regression to consider the contribution of metabolic
measures at different ages. Based on the correlation re-
sults, we contrasted Phe average and Phe variation taken
in childhood with the same measures taken either in
adolescence or adulthood. All measures were entered to-
gether in the regression equation to see which
combination predicted cognition best (SPSS forward
method). In this analysis the order in which the variables
are entered in the equation is identified by the regression
model. The variable making a stronger contribution is
entered first following by any other variable making an
additional, significant contribution. We considered ei-
ther adult or adolescent values in separate analyses be-
cause of their high correlation (for Phe average r = .74;
for Phe variation r = .50) and becaue we wanted to
avoid power with more variables.
Results
Relative contribution of Phe average vs Phe SD in
childhood vs adulthood
An inspection of Table 3 suggests that different meta-
bolic measures have different effect on cognition at dif-
ferent ages. Considering ages further apart, we
statistically compared correlations with Phe average and
Phe SD in childhood and adulthood. Within childhood
measures, there was a higher number of significant cor-
relations and a higher mean correlation with Phe SD
than with Phe average (12/16 vs 5/16; χ2 = 6.1; p = .01;
Pearson r = .30 vs .16; t-test = 6.4; p < .001). The opposite
was true for adult measures. Here, there was a higher
number of significant correlations and a higher mean
correlation with Phe average than with Phe SD (10/16 vs
5/16; χ2 = 3.1; p = .08; Pearson r = .27 vs .19; t-test = 2.3
p < .03). Importantly, the different degree of association
of Phe variations with cognitive performance at different
points in life was not due to differences in variability
since Phe variation was similar across the life span (see
Table 1). These results suggest that Phe average and Phe
variation impact on the brain through different mecha-
nisms since their effect differ at different ages. If this is
the case, we should be able to demonstrate that both
these measures contribute independently to explain
adult cognitive outcomes.
Independent contribution of Phe average vs Phe SD
Results of regression analyses are shown in Tables 4 and
5. Table 4 shows two analyses. Analysis A is a two-steps
regression where education was entered in the first step
and Phe average and Phe SD were entered together in
the second step. Results suggest that education influ-
ences IQ, but not cognitive performance in our battery
(mean z-score). Crucially, results also show that Phe SD
is the main predictor of both IQ and overall z-score. Phe
average, however, also makes a (marginally significant)
contribution to explain mean z-score. Analysis B is a
two-steps regression where Phe average was entered in
the first step and Phe SD in the second step. Results in-
dicate that Phe SD is a significant predictor of perform-
ance even when the contribution of Phe average is
partialled out, explaining a significant additional amount of
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variation both in IQ (27%) and mean z-score (23%). Phe
average makes a smaller, marginally significant contribu-
tion, explaining 16% of variance in mean z-scores.
Table 5 shows the relative contribution of Phe mea-
sures (average and SD) taken either during childhood or
adolescence/adulthood. Results show that IQ is pre-
dicted only by adolescent/adult Phe average. Mean z-
score instead is predicted by both childhood Phe SD and
adolescent/adult Phe average. These variables to-
gether predict a particularly high proportion of variance
in mean z-score (41 and 43% respectively in a regression
including either adolescent or adult Phe average).
Conclusion
Overall these results highlight the importance of consid-
ering both Phe variation (especially in childhood) and
Phe average levels (especially in adulthood) as predictors
of adult cognitive outcomes.
Individual variability in cognitive outcomes
Data analyses
To examine individual variability in cognitive outcomes,
we performed three different types of analyses.
First of all, we compared the distribution of cognitive
scores in PKU and control participants to see if shifts in
performance involved the whole distribution or only the
bottom part of the distribution. For this purpose, we have
divided both PKU and control groups into thirds according
to best vs worse performance for IQ and mean z-score.
Then, we have performed a between-subjects Anova with
group (PKU vs control) and subgroup (top third vs bottom
third) as independent variables and either IQ or mean z-
score as a dependent variable.
Second, we examined the distribution of cognitive
scores in relation to metabolic control. We first visually
examined scatter plots to see if the Phe boundaries iden-
tified by current European guidelines were meaningful
in eliminating/reducing individuals with poor scores.
Then, we used χ2 tests to compare the proportions of in-
dividuals with poor cognitive scores whose metabolic
control was or not within the guideline boundaries. Ar-
bitrarily, we considered ‘poor’ scores, which were = > 1
z-score from the control group. In a normal distribution,
this would apply to 16% of scores.
Lastly, we assessed if we could identify any exceptional
cases in our data-base where poor Phe control was associ-
ated with good cognitive performance. To be conservative,
we identified as having poor control any individuals with
average Phe levels (in either childhood and adolescence) ex-
ceeding both European guidelines and the average for the
PKU group (= > 500 in childhood and = > 900 in either ado-
lescence and adulthood). To be conservative, we identified as
Table 4 Regression analyses predicting cognitive outcomes from Phe variation (SD) and Phe average entered either at the same
step (forward method; set A) or at different steps (set b). Phe variation and Phe average are computed across the life-span.
Coefficient and p refer to best model
Dependent variable R2 Adj R2 Predictors stand β p R2 change
Analysis-A
Full IQ Step 1 0.16 0.14 Education .28 .01
Step 2 0.39 0.37 Phe SD −0.5 <.001
Phe average – –
Mean z-score Step 1 0.09 0.08 Education −19 .09
Step 2 0.42 0.39 Phe SD .46 <.001
Phe average .23 .049
Analysis B
Full IQ Step 1 0.05 0.03 Phe average −.03 n.s. –
Step 2 0.32 0.29 Phe SD −.55 <.001 0.27
Mean z-score Step 1 0.16 0.14 Phe average .22 .06 –
Step 2 0.39 0.36 Phe SD .51 <.001 0.23
Table 5 Simultaneous regression analyses –method forward--
predicting cognitive outcomes from: a) Childhood Phe average;
b) childhood Phe SD; c) adolescent/adult Phe average; d)
adolescent/adult Phe SD. Analysis A uses adolescent measures;
Analysis B uses adult measures
Dependent
Variables
Predictors Best model
Entered R2 Adj R2 stand β p
Analysis - A
Full IQ Adolescent Phe average .23 .21 −0.48 .001
Mean z-score Adolescent Phe average .43 .41 0.38 .01
Childhood Phe SD 0.36 .01
Analysis - B
Full IQ Adult Phe average .22 .20 −0.47 .001
Mean z-score Childhood Phe SD .41 .39 0.41 .005
Adult Phe average 0.32 .02
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having good cognition any individuals where IQ was within
.05 z-score from controls, mean z-score was average (=0) or
better than average (negative), and where there was a normal
incidence of very poor z-scores (= > 1.5) across tasks (this
proportion is on average 6% in the control group).
Results
Distribution of cognitive scores in PKU and control groups
Figure 1 compares results for the PKU and control sub-
groups depending on how their performance ranked within
their group (best or worse third). Results were mixed. The
PKU group was always worse than the control group, but
differences were more marked for the worst subgroups. In
fact, there was a significant interaction of group (PKU vs
control) x subgroup (best vs worst third) with z-scores (F
(1,65) =7.1; p = .01) and a marginal difference with IQ (F (1,
65) =2.7; p = .10). These results indicate that, if there is a
fixed cost of having PKU, this is marginal.
Distribution of scores in relation to metabolic control
Figure 2 shows the distributions of IQ scores and z-scores
in relation to metabolic measures: Phe average and Phe
variation in childhood (Panel A) and Phe average and Phe
variation in adolescence/adulthood (Panel B). To reduce
the number of plots, we have averaged measures in adoles-
cence and adulthood since these are highly correlated and
similarly related to cognitive outcomes as shown by the re-
gression analyses. With few exceptions, poor scores corres-
pond to individuals who have not followed the guidelines
(Phe levels = > 360 in childhood and/or = > 600 after that).
Additionally, there are few or no individuals with poor z-
scores and Phe variation < 180 in childhood and in adoles-
cence/adulthood. There are more individuals with poor IQ
and Phe variation < 180 in adolescence/adulthood, but note
that even here Phe variation is a good predictor of perform-
ance as shown by the slope of the regression line.
Table 6 shows the number and % of individuals with
poor cognitive scores in relation to guideline adherence.
Numbers are small so exact values are not very mean-
ingful, but patterns are clear. In all cases, there is a
higher % of individuals with poor scores among those
who have not followed guidelines and in most cases dif-
ferences are significant. In particular, the risk of poor
cognitive performance is about 30% higher in individuals
who have relaxed the diet after childhood.3
Exceptional cases
In our sample, following our definition, there were 13
participants with poor metabolic control in childhood
(average Phe= > 500); 12 with poor metabolic control in
adolescence (average Phe= > 900) and 27 with poor
metabolic control in adulthood (average Phe= > 900).
Following our criteria, out of these participants, we
could identify only 3 individuals with completely normal
cognition and poor metabolic control in adulthood (3/
27 = 11%). Their profile is shown in Table 7. We could
not identify any individuals with poor control in child-
hood and adolescence and good cognition, but our sam-
ples are small. Also note that our definition of ‘good’
cognition was strict and included performance in our
ad-hoc PKU cognitive battery. If we consider cognition
only in terms of IQ, a larger proportion of participants
have allegedly normal cognition (IQ within .5 SD from
the control mean), but poor control in childhood: 4/13;
adolescence: 4/12; and adulthood: 6/27. Across ages, we
found 14/52 exception cases considering only IQ vs 3/54
considering cognition more widely (χ2 = 7.0; p = .008).
Discussion
Our study had two main aims: 1. to compare the effects
of average Phe levels and Phe variation/fluctuation (in
terms of Phe SD) on cognitive functions and 2. to ex-
plore cognitive variability in relation to metabolic con-
trol in a population of adults with PKU.
First of all, our results showed developmental interac-
tions between type of cognitive function and type of meta-
bolic measure (average vs SD). Different functions were
affected by historical vs current metabolic control and by
Phe average vs. Phe SD. Speed of processing in visual
search was affected by metabolic control in childhood
measured by both Phe median levels and Phe SD, while
current Phe level had little impact [57]. Other tasks corre-
lated significantly with current Phe --especially those in-
volving visuo-motor coordination (digit symbol), learning
and memory, an executive component (reasoning: IQ;
flexibility: TMT B-A) and sustained attention (RVP). Con-
sistent with our results, Moyle et al. [18] also found that a
group of young adults with PKU (N = 12) showed signifi-
cant differences from controls (N = 12) with the Process-
ing Speed Index from the WAIS, but no correlations with
current Phe level. The opposite was true for a memory
index (WMS-III), where there was no impairment, but a
strong correlation with current Phe levels (except for
short-term memory, as in our case). Additionally, our re-
gression analyses showed that, overall, adult cognition was
best predicted by a combination of Phe childhood SD and
Phe adolescence/adult averages.
These results suggest that there are different mecha-
nisms through which Phe impact on cognition. High
Phe may cause changes in levels of neurotransmitters
(e.g., lowering dopamine) which can be modulated rela-
tively short-term [60]. Alternatively, high Phe may affect
brain structures (e.g., white matter; see Anderson et al. [61];
3Results were in the right direction but did not reach significance
when we considered childhood average levels. This may simply be
error variation due to our small sample; childhood Phe average, in fact,
was also significantly correlated with adult outcomes.
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Anderson & Leuzzi, [62]) in a way which can be effective
only during some critical periods and/or can be appreciated
only long-term. Our results do not support one hypothesis
of impairment versus another, but indicate that different
mechanisms must be at play. This is necessary to explain
our results showing that Phe average and Phe SD have a
different impact on cognition at different ages. Possibly,
Phe peaks are more detrimental for developing brains be-
cause they impact on white matter structural integrity [18,
63], while cumulative effects of Phe --as indexed by Phe av-
erages—may be more detrimental for adult brains because
they also impact on levels of neurotransmitters.
Clinically, our results indicate the importance of keep-
ing low both Phe average and Phe variation. Regression
analyses showed that Phe variation throughout the life-
span was a stronger predictor of IQ and performance in
our cognitive battery (mean z-score) although both Phe
average and Phe variation across the life-span contrib-
uted to determine mean z-score. Together, childhood
Phe variation and adult average levels accounted for as
much as 41% of variability in overall z-score.
Regarding cognitive variability, our results confirmed ex-
treme variability in cognitive outcomes across individual
PKU participants. AwPKU in the top third of a distribution
of cognitive scores performed very well. In fact, they per-
formed almost as well as the control participants in the top
third of their distribution. This suggests that the cognitive
costs of PKU are minimal beyond those associated with high
levels of Phe. If Phe levels are kept in check, performance
can be (almost) as good as in the best controls. Minor costs
could be associated to living with a chronic disease and/or
with the fact that Phe control is not perfect even in
individuals with top cognitive performance. This is in
contrast with participants in the bottom third of the
distribution who showed substantial impairments
across a wide range of tasks.
Importantly, considering the distributions of cognitive
scores in relation to metabolic control, we found that
maintaining Phe < 600 after childhood significantly
reduced the risk of poor cognitive outcomes by around
30%. This was true both when performance was mea-
sured by IQ and when it was measured as mean z-score
in our cognitive battery. We also found that reduced Phe
variation in childhood and afterwards significantly re-
duced the risk of poor outcomes (= > 1 z-score from
controls) by a similar amount. These results, together
with the results of our regression analyses, provide evi-
dence for maintaining a good and stable dietary control
after childhood. Distinguishing the contribution of meta-
bolic control in adulthood and adolescence is more diffi-
cult given that these measures are highly inter-
correlated. However, the significant effect of current Phe
on specific tasks suggests that dietary control continu-
ously modulates cognition, at least in some domains.
Our sample included a few individuals with poor
metabolic control in adulthood, but excellent cogni-
tion. It is difficult to know if these individuals could
have achieved even better cognition if they had main-
tained a low Phe diet, but these cases do raise the
question of some possible protective factors in some
individuals where the effects of high Phe levels are
not evident. Reduced transport of Phe through the
blood-brain-barrier could be one such factor although
high levels of Phe were still found in the CSF of one
these individuals described in the literature [64]. Re-
cently van Vliet et al. [37] has reviewed exceptional
cases from the literature of untreated individuals with
PKU who have escaped mental disability. One has to
stress, however, that these cases are very few. In our
sample there were only three cases with good cogni-
tion and poor metabolic control in adulthood (Phe
= > 900 μ/L; N = 3/27 = 11%) and no cases with good
cognition and poor metabolic control at earlier ages.
Finally, we note the importance of using ad-hoc, compre-
hensive batteries to test and monitor cognition in people
with PKU. Phe measures were more related to variance in
our cognitive battery than in IQ (see Table 5). Moreover,
the proportion of individuals who apparently achieved good
Fig. 1 Differences between PKU and controls when individuals with best and worst performance in each group are compared (best 1/3
compared to worse 1/3). Bars show standard errors
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cognition in spite of poor metabolic control was higher
when cognition was measured only through IQ. It is im-
portant to consider cognition comprehensively to avoid
false negatives of no consequences of relaxing the diet
when, in fact, there is a clear impact in some cognitive
areas.
Study limitations
The main limitation of our study is the number of par-
ticipants which interacts with the characteristics of
metabolic control in samples of adults with PKU. It is
difficult to evaluate whether metabolic control in adult-
hood contributes to cognitive outcomes above metabolic
control in adolescence since these two measures are
highly correlated. We need larger samples where these
variables dissociate. Moreover, metabolic control is often
good in childhood and adolescence and this reduces
sample sizes when we want to assess the consequences
of following the diet less strictly at these ages. Again, a
larger sample will help to identify these cases. More
Fig. 2 Cognitive outcomes in terms of IQ and overall z -score in our cognitive battery in relation to metabolic control. Panel A shows metabolic
control in terms of Phe average levels in childhood and later on. Panel B shows metabolic control in term of Phe variation in childhood and later
on. Note z-scores are depicted in figure so that both high IQ and high z-scores indicate good performance. The top horizontal line indicates
average performance according to control group. The bottom horizontal line indicates performance = < 1SD from control average (FIQ for
controls = 112.3; SD = 11.3; cut off 1 SD = 101). The black dots correspond to poor scores. The vertical lines indicate possible safety criteria (for Phe
average < 360 in childhood < 600 afterwards; for SD < 180)
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collaborations across clinics are necessary to achieve ad-
equate sample sizes.
Conclusions
Our study has furthered our understanding of PKU in two
main ways. We have demonstrated developmental effects
where outcomes depend on complex interactions between
the cognitive function examined, the age when metabolic
control is measured (childhood, adolescence, current level)
and the type of metabolic variable considered (Phe average
vs Phe variation). Significant effect of childhood Phe levels
on adult cognitive performance decades later support the
idea of critical periods for brain development where high
Phe levels and particularly Phe peaks (Phe variation) are very
detrimental [65]. Significant correlations between current or
adult average Phe levels and cognitive performance are con-
sistent with the alternative, but not mutually exclusive, view
that the toxic effect of Phe cumulate throughout the lifetime
(for an overview on this topic see Berry et al. [66]).
Secondly, our study has provided evidence broadly
consistent with the safety of following current European
guidelines to avoid cognitive impairments. Levels < 360
μmo/l in childhood and < 600 μmo/l in adulthood pre-
vent cognitive impairments. We have also suggested,
however, that maintaining low Phe variation should be
an equally important criterion when setting guidelines.
In, our sample SD < 180 was also instrumental in pre-
venting poor cognitive scores. While guidelines, should
be followed to avoid poor outcomes, the presence of a
few cases with high adult Phe level, but excellent cogni-
tion suggests that there is individual variability in Phe
sensitivity. Given the social and economic costs of main-
taining a low Phe diet, identifying who and why may
avoid a strict diet without cognitive drawbacks should be
one of the priorities of future research.
Table 6 Number and percentages of poor cognitive scores in individuals who have followed or not followed European guidelines
(Phe average < 360 in childhood; < 600 after that); Poor cognitive scores = > 1 SD worse than the controls. Z-score = mean z score in
our cognitive battery
Childhood 0–10 Adolescence/Adult 11+
Guidelines Diff. χ2 Guidelines Diff. χ2
✓ ✓
Phe AVERAGE Phe < 360 Phe > 360 p Phe < 600 Phe > 600 p
IQ N 10/22 16/28 4/15 23/41
% 45.5 57.1 11.7 .30 26.7 56.1 29.4 .05
z-score N 3/22 9/28 0/15 12/41
% 13.6 26.5 12.8 .12 0 29.3 29.3 .01
Phe SD Phe < 180 Phe > 180 Phe < 180 Phe > 180
IQ N 5/14 21/34 15/38 11/18
% 35.7 61.8 26.1 .09 42.2 61.1 19.0 .11
z-score N 0/14 12/34 5/38 -7/18
% 0 35.3 35.3 .008 13.6 38.9 25.7 .03
Table 7 Performance of potentially exceptional participants
with good cognition in spite of poor metabolic control or vice-
versa poor cognition in spite of good control (see text for
further explanation). Childhood Phe results for PKU108 are not
available
Good cognition but poor adult control
PKU4 PKU107 PKU108
IT UK UK
Age 24 40 27
Education (in years) 13 14 16
Gender (M/F) M M M
Full IQ 109 117 126
Feature search RT −0.1 −0.3 −1.1
Conjoined search RT 0.1 −0.5 −1.4
Pegboard 0.1 −0.6 1.1
Average Z score 0.1 0.0 −0.2
% z score = > 1.5 4.2 8.3 8.3
Childhood (0–10 y)
Phe Average Median 498 425 –
Phe Variation 181 213 –
Adolescence (11–16 y)
Phe Average Median 634 622 845
Phe Variation 634 113 150
Adulthood (17 y +)
Phe Average Median 1067 1115 1000
Phe Variation 239 114 137
Lifetime
Phe Average Median 672 978 975
Phe Variation 169 148 139
Current Phe 1635 1080 685
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Appendix
Table 8 Raw scores for PKU (N = 50–56) and controls (N = 49); Highlighted results are significantly different between the two groups
(see Table 2)
PKU raw score Controls raw score
Mean SD Mean SD
Visual attention RTs
Simple Detection - ms. 329.3 49.9 315.5 52.0
Detention with Distractors – ms. 464.2 93.0 411.8 63.8
Feature Search – ms. 661.5 217.9 532.2 98.5
Conjunction Search m. 1062.7 246.6 878.3 165.4
Visual attention accuracy
Detention with Distractors - % errors 0.8 1.0 0.6 0.9
Feature Search - % errors 1.6 3.5 1.5 2.1
Conjunction Search - % errors 2.2 3.5 1.6 4.5
Visuo-motor coordination
Pegboard (sec.) 73.6 13.1 67.6 7.9
Digit Symbol (%errors in 90 s.) 38.9 11.7 26.0 10.0
Trail-Making Test A: (sec.) 27.6 12.0 23.8 9.6
Executive functions
WCST
Total errors 13.9 7.7 11.9 5.2
Perseverative responses 7.7 4.5 7.2 4.0
N of Completed Categories 3.9 1.1 4.3 0.9
Trail-Making Tests
B (sec.) 56.2 29.2 45.9 17.5
B-A (sec.) 28.7 23.2 22.1 13.2
Verbal Fluency
Letter (correct answers) 37.0 11.1 44.0 11.9
Semantic (correct answers) 20.9 5.7 24.4 4.52
Short term memory
Digit span 6.0 1.0 6.3 1.0
Corsi Block span 5.5 0.9 5.4 1.0
Sustained attention
RVP (% of errors) 20.6 11.8 14.3 9.1
Learning
Rey Auditory Verbal Learning Test
Trial A1-A5 (% errors) 22.8 10.4 20.2 7.5
Retention (% errors A6) 17.9 14.5 12.9 13.8
Delayed Recall (% errors) 14.0 14.3 11.2 13.4
Paired Associate Visual learning
(% errors) 2.8 3.3 1.7 1.7
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